Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Poxviruses: Novel Concepts and Emerging Trends"
Deadline for manuscript submissions: 1 January 2021.
All viruses need to infect, replicate, and transmit whilst they deal with host defensive processes. Poxviruses are evolutionarily successful viruses able to infect insects (entomopoxviruses) and chordates (chordopoxviruses), including fish, reptiles, aves, and mammals. To achieve this, poxviruses have evolved complex strategies to hijack cellular resources, subvert host antiviral responses, and produce multiple infectious forms adapted to cell-to-cell or host-to-host transmission. In some cases, this sophistication has led to narrow host range, sometimes restricted to one species, the most notorious of which was the human-specific variola virus that caused smallpox. Our knowledge on poxviruses has been driven by research on the prototypic member vaccinia virus, the smallpox vaccine, and a popular vaccine vector and oncolytic agent. However, many crucial insights into poxvirus biology and host antiviral defence have arisen from work with animal poxviruses like cowpox, ectromelia, and myxoma viruses. Over the last decade, transcriptomics and proteomics approaches have allowed us to uncover new details of how poxviruses enter cells, transcribe and translate their genetic information, and assemble new progeny viral particles. Equally, major breakthroughs have been reported on host sensing mechanisms and responses and poxvirus immune evasion strategies, with the implications these might have on the development of safer and more effective vaccines and oncolytics. In addition, deep-sequencing technologies are unravelling the genomes of novel poxvirus species, shedding light on the evolutionary history of the family and its strategies for adaptation. It is in this context of exciting discoveries and emerging concepts that Pathogens will launch a Special Issue on Poxviruses that aims to collect insightful reviews and perspectives on the biology of these unique viruses and their vast impact on human and animal medicine. Potential topics include but are not limited to molecular and cell biology of poxviruses; virus–host interactions; tropism; animal and human health; and biomedical applications.
I very much look forward to receiving your contributions for this exciting Issue.
Dr. Carlos Maluquer De Motes
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- vaccinia virus
- variola virus
- cowpox virus
- ectromelia virus
- monkeypox virus
- smallpox vaccine
- virus entry
- virus replication
- virus-host interactions
- virus immune evasion
- virus tropism
- virus evolution
- vaccine vectors
- oncolytic agents